Rates of grade 3/4 hematologic adverse events and biochemical abnormalities
| . | Treated patients, n (%) . | |
|---|---|---|
| Dasatinib, N = 258 . | Imatinib, N = 258 . | |
| Hematologic adverse events | ||
| Neutropenia | 61 (24) | 53 (21) |
| Thrombocytopenia | 50 (19) | 29 (11) |
| Anemia | 29 (11) | 20 (8) |
| Biochemical abnormalities | ||
| Hypophosphatemia | 17 (7) | 64 (25) |
| Hypocalcemia | 8 (3) | 5 (2) |
| Hypokalemia | 0 | 6 (2) |
| Elevated alanine aminotransferase | 1 (< 1) | 4 (2) |
| Elevated aspartate aminotransferase | 1 (< 1) | 2 (1) |
| Elevated total bilirubin | 3 (1) | 0 |
| Elevated creatinine | 3 (1) | 2 (1) |
| . | Treated patients, n (%) . | |
|---|---|---|
| Dasatinib, N = 258 . | Imatinib, N = 258 . | |
| Hematologic adverse events | ||
| Neutropenia | 61 (24) | 53 (21) |
| Thrombocytopenia | 50 (19) | 29 (11) |
| Anemia | 29 (11) | 20 (8) |
| Biochemical abnormalities | ||
| Hypophosphatemia | 17 (7) | 64 (25) |
| Hypocalcemia | 8 (3) | 5 (2) |
| Hypokalemia | 0 | 6 (2) |
| Elevated alanine aminotransferase | 1 (< 1) | 4 (2) |
| Elevated aspartate aminotransferase | 1 (< 1) | 2 (1) |
| Elevated total bilirubin | 3 (1) | 0 |
| Elevated creatinine | 3 (1) | 2 (1) |